Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of thonningianin A in the preparation of drugs for preventing or treating alcoholic cardiomyopathy

A technology of alcoholic cardiomyopathy and drugs, which is applied in drug combination, cardiovascular system diseases, and pharmaceutical formulations, etc., can solve the problems of left ventricular cardiomyocyte loss, mitochondrial damage, and cardiac insufficiency, and achieve the recovery of heart damage and recovery. Myocardial injury, reduce the effect of myocardial injury

Active Publication Date: 2020-02-21
ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the pathogenesis of alcoholic cardiomyopathy is not yet clear. Studies have shown that a large amount of alcohol can cause the loss of left ventricular cardiomyocytes, which in turn can cause cardiac insufficiency, mitochondrial damage, calcium homeostasis imbalance, changes in myocardial contractile proteins, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of thonningianin A in the preparation of drugs for preventing or treating alcoholic cardiomyopathy
  • Application of thonningianin A in the preparation of drugs for preventing or treating alcoholic cardiomyopathy
  • Application of thonningianin A in the preparation of drugs for preventing or treating alcoholic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] 1. Materials:

[0030] Experimental animals: 50 C57BL / 6 male mice were purchased from Shanghai Slack Experimental Animal Co., Ltd., company license number: SCXK (Shanghai) 2017-0005, and were kept in the Experimental Animal Center of Zhejiang University of Traditional Chinese Medicine in an SPF environment.

[0031] Reagent: Thonningianin A (TA); Lieber-DeCarli alcohol liquid model feed (product code TP-4030B, Nantong Trophy Feed Technology Co., Ltd.); Lieber-DeCarli control liquid feed (product code TP-4030BC, Nantong Trophy Feed Technology Co., Ltd.); choline, vitamins (Nantong Trofe Feed Technology Co., Ltd.); absolute ethanol (CAS-NO: 64-17-5, lichrosolv); creatine kinase isoenzyme (Lot: N28018610, CUSABIO) .

[0032] 2. Method:

[0033] After the C57BL / 6 mice were adapted to feeding in the SPF level animal laboratory, the 8-week-old C57BL / 6 mice were randomly divided into 5 groups, 10 in each group, respectively, the control liquid feed group (PF group), the alco...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of Thonningianin A to the preparation of A drug for preventing or treating alcoholic cardiomyopathy. The Thonningianin A (TA) provided by the invention significantly reduces the plasma CK-MB content in an alcoholic cardiomyopathy model, and the reduction by high dose of TA is 38.12%, thereby restoring cardiac ejection ability and alleviating cardiac hypertrophy in alcoholic cardiomyopathy, and significantly reducing myocardial damage caused by the alcoholic cardiomyopathy model. At present, the clinical manifestations of the alcoholic cardiomyopathy areoften accompanied by cardiac dilatation and congestive heart-failure, especially left ventricular failure prevails. TA can effectively restore the increased left ventricular posterior wall thickness and myocardial damage, so TA effectively alleviates the cardiac trauma caused by an alcohol diet model.

Description

[0001] (1) Technical field [0002] The present invention relates to a new application of Thonningianin A (TA), that is, the application of Thonningianin A in the preparation of drugs for preventing or treating alcoholic cardiomyopathy. [0003] (2) Background technology [0004] Alcohol cardiomyopathy (alcoholic cardiomyopathy, ACM) is a growing disease in the cardiovascular field, a secondary heart disease caused by long-term alcohol consumption leading to myocardial degeneration, heart enlargement and heart failure. Alcohol abuse is the leading cause of nonischemic cardiomyopathy in the United States, accounting for approximately 3.8% of all cardiomyopathy. Chronic alcohol intake has been reported to be a major cause of congestive heart failure due to dilated cardiomyopathy, a form of congestive heart failure that accounts for approximately 35% of cases of nonischemic dilated cardiomyopathy. At present, the pathogenesis of alcoholic cardiomyopathy is not yet clear. Studies ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P9/00
CPCA61K31/7048A61P9/00
Inventor 李松涛丁滨丁秦超柴惠窦晓兵
Owner ZHEJIANG CHINESE MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products